GGrantIndex
Sort

51,593 grants matching hepatitis

In silico identification of phyto-therapies

$379,655
Indra N Sarkar · Brown University · R01 · FY2015 · LM

Community Outreach and Engagement

$379,609
Moon S Chen · University Of California At Davis · P30 · FY2021 · CA

Adult to adult living donor liver transplantation cohor*

$379,606
James F. Trotter · University Of Colorado Denver · U01 · FY2007 · DK

Core 3: Population & Data Modeling

$379,570
Bruce R Schackman · Weill Medical Coll Of Cornell Univ · P30 · FY2023 · DA

Mechanisms for Arsenic-Induced Vascular Disease

$379,561
Aaron Barchowsky · University Of Pittsburgh At Pittsburgh · R01 · FY2009 · ES

Point-of-care magnetofluidic HCV diagnostic using thermally responsive valves

$379,560
Ian M White · Univ Of Maryland, College Park · R01 · FY2025 · AI

Evolution of Virus-Host Interactions

$379,546
John Yin · University Of Wisconsin-Madison · R01 · FY2012 · AI

Novel Anti-Diabetic Actions of Hypothalamic FGF19-FGFR1 Signaling

$379,538
Michael W Schwartz · University Of Washington · R01 · FY2015 · DK

Ricin-Mechanism, Transition State and Inhibitor Design

$379,534
Vern L. Schramm · Albert Einstein College Of Medicine · R01 · FY2010 · CA

REGULATION OF NET HEPATIC GLUCOSE UPTAKE IN VIVO

$379,519
Vanderbilt University · R01 · FY2000 · DK

Apolipoprotein A-V: A Functional Proteomics Study

$379,509
Robert O'Mara Ryan · Children'S Hospital & Res Ctr At Oakland · R01 · FY2007 · HL

New Targets of Thyroid Hormone Action

$379,505
Anthony N Hollenberg · Beth Israel Deaconess Medical Center · R01 · FY2017 · DK

Regulation of polycystin-2 channel activity

$379,492
Titus Jonathon Boggon · Yale University · R01 · FY2013 · DK

Control of Effector and Memory T Cell Development by Inflammatory Signals

$379,454
Susan M Kaech · Yale University · R01 · FY2012 · AI

GENE THERAPY FOR DYSLIPIDEMIAS

$379,448
Daniel James Rader · University Of Pennsylvania · P01 · FY2013 · HL

Role of the Gut Microbiota and TLR4 in Alcoholic Hepatocarcinogenesis

$379,439
Robert F. Schwabe · Columbia University Health Sciences · R01 · FY2013 · AA

Development and Validation of a Zebrafish Model for Vanishing White Matter Disease

$379,420
Josh Leitch Bonkowsky · University Of Utah · R33 · FY2022 · NS

METABOLIC EFFECTS OF PROTEASE INHIBITORS IN HIV DISEASE

$379,416
University Of California San Francisco · R01 · FY2001 · DK

Optical and electromagnetic tracking guidance for hepatic interventions

$379,411
Umar Mahmood · Massachusetts General Hospital · U01 · FY2018 · CA

Prospective evaluation of outcomes in cirrhosis of different etiologies: impact of HIV infection and simvastatin therapy

$379,411
Srinivasan Dasarathy · Cleveland Clinic Lerner Com-Cwru · U01 · FY2021 · DK

Hepatitis C virus escape mechanisms from innate immunity

$379,384
Ranjit Ray · Washington University · U54 · FY2009 · AI

Effect of HBV DNA Methylation and the Mutant 1762T/1764A on Viral Load and HCC

$379,361
Kathleen Schwarz · Johns Hopkins University · U01 · FY2010 · DK

Longitudinal cohort of newly acquired HCV infection

$379,345
John M Kaldor · University Of New South Wales · R01 · FY2007 · DA

Heart and Skeletal Muscle Metabolism, Energetics and Function in Barth Syndrome

$379,329
William Todd Cade · Washington University · R01 · FY2016 · HL

Alcoholic Hepatitis Clinical and Translational Network Late Phase Clinical Trials and Observational Studies 8/9

$379,324
Mack Clarence Mitchell · Ut Southwestern Medical Center · U01 · FY2020 · AA